Fleddermann A, et al. - Whether direct acting oral anticoagulants (DOACs) are safe and effective for the treatment of left ventricular (LV) thrombus, was investigated in this study by utilizing transthoracic echocardiography (TTE) findings and clinical outcomes from patients (mean age = 64 years, 71% men) who received a DOAC for the treatment of LV thrombus (n = 26 apixaban, n = 24 rivaroxaban, and n = 2 dabigatran). Follow-up TTE was performed in 35 patients, of whom, resolution of LV thrombus was evident in 29 patients, with a mean duration of 264 days. Fifty-two days after DOAC initiation, 1 cardioembolic event (transient ischemic attack) was reported. Also, 3 gastrointestinal bleeds and 1 epistaxis requiring transfusion were reported. Overall, DOAC therapy seemed promising for the treatment of LV thrombus.